

Brady L Stein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9633847/publications.pdf>

Version: 2024-02-01

58
papers

1,058
citations

471509

17
h-index

414414

32
g-index

58
all docs

58
docs citations

58
times ranked

1880
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2534-2536.	3.8	10
2	Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 483-489.	2.3	2
3	Improving Hematology Clinic Access for Patients with Cancer-Associated Thrombosis. <i>Blood</i> , 2021, 138, 1885-1885.	1.4	1
4	Long-term antithrombotic therapy after venous stent placement. <i>Phlebology</i> , 2020, 35, 402-408.	1.2	11
5	Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency. <i>Bone</i> , 2020, 141, 115559.	2.9	9
6	Thrombocytosis and Thrombosis: Is There Really a Correlation?. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 261-267.	2.3	14
7	Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Cancer Treatment and Research</i> , 2019, 179, 159-178.	0.5	16
8	Myelofibrosis in 2019: moving beyond JAK2 inhibition. <i>Blood Cancer Journal</i> , 2019, 9, 74.	6.2	53
9	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 397-406.	2.5	17
10	From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 1902-1911.	1.4	20
11	<i>ASXL1</i> mutations in idiopathic cytopenias: determined significance?. <i>Leukemia and Lymphoma</i> , 2019, 60, 568-570.	1.3	0
12	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis. <i>JAMA Oncology</i> , 2018, 4, 652.	7.1	261
13	Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of <i>Mycoplasma pneumoniae</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1377.	7.4	9
14	Cold Agglutinins in Mycoplasma Infectionâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1039.	7.4	0
15	Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 788-795.e2.	0.4	19
16	Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 590-596.	0.4	22
17	Incidence of solid tumors or lymphoma in patients with polycythemia vera: Data from the REVEAL study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19029-e19029.	1.6	0
18	Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. <i>Leukemia and Lymphoma</i> , 2017, 58, 2786-2798.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. <i>International Journal of Hematology</i> , 2017, 105, 44-51.	1.6	15
20	Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1238-1245.	4.9	11
21	Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. <i>EBioMedicine</i> , 2016, 3, 17-25.	6.1	6
22	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts $\leq 100,000/\mu\text{l}$. <i>Blood</i> , 2016, 128, LBA-5-LBA-5.	1.4	29
23	Disease, clinical, and treatment characteristics of patients (pts) with polycythemia vera (PV) enrolled in the REVEAL study. <i>Journal of Clinical Oncology</i> , 2016, 34, e18557-e18557.	1.6	1
24	Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study. <i>Journal of Clinical Oncology</i> , 2016, 34, e18561-e18561.	1.6	0
25	The Need for United States-Based Guidelines for Myeloproliferative Neoplasms. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 607-609.	4.9	4
26	Central Role of ULK1 in Type I Interferon Signaling. <i>Cell Reports</i> , 2015, 11, 605-617.	6.4	66
27	Novel therapies for myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2768-2778.	1.3	7
28	Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. <i>International Journal of Hematology</i> , 2015, 102, 587-593.	1.6	27
29	Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis. <i>Thrombosis</i> , 2015, 2015, 1-5.	1.4	7
30	Disease Characteristics and Prognosis of Myelodysplastic Syndrome Presenting with Isolated Thrombocytopenia. <i>Blood</i> , 2015, 126, 3477-3477.	1.4	2
31	Burden of Phlebotomy in Patients with Polycythemia Vera in the United States: Baseline Data from the REVEAL Study. <i>Blood</i> , 2015, 126, 5187-5187.	1.4	5
32	Permanent inferior vena cava filters in patients with active malignancy. <i>Journal of Clinical Oncology</i> , 2015, 33, e17655-e17655.	1.6	0
33	Self-Reported Quality-of-Life Impairment and Productivity Loss in Patients with Polycythemia Vera: Early Patient-Reported Outcomes Assessment from the REVEAL Study. <i>Blood</i> , 2015, 126, 4084-4084.	1.4	0
34	Disease and Clinical Characteristics of Patients with Polycythemia Vera: An Early View of the Reveal Study. <i>Blood</i> , 2015, 126, 2813-2813.	1.4	0
35	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. <i>Journal of Biological Chemistry</i> , 2014, 289, 6581-6591.	3.4	19
36	Regulatory effects of SKAR in interferon \pm signaling and its role in the generation of type I IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11377-11382.	7.1	11

#	ARTICLE	IF	CITATIONS
37	Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. <i>Annals of Hematology</i> , 2014, 93, 1965-1976.	1.8	34
38	Essential Thrombocytosis: Redefinition in the Genomic Era. <i>Blood</i> , 2014, 124, 3205-3205.	1.4	0
39	A Phase 1/2, Open-Label, Dose-Escalation, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF). <i>Blood</i> , 2014, 124, 1839-1839.	1.4	2
40	Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib. <i>Blood</i> , 2014, 124, 1834-1834.	1.4	1
41	Prevalence, Type, and Risk Factors for Bleeding in a Large Cohort of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2014, 124, 3207-3207.	1.4	0
42	Temporary Vena Cava Filters in Oncology Patients. <i>Blood</i> , 2014, 124, 4247-4247.	1.4	0
43	Diagnosis and Management of Polycythemia Vera in the Post-JAK2 V617F Discovery Era: A Survey of Practice Patterns. <i>Blood</i> , 2014, 124, 2172-2172.	1.4	1
44	Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 145-153.	1.2	38
45	Thrombotic and Bleeding Complications in Classical Myeloproliferative Neoplasms. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 101-111.	2.7	32
46	Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. <i>Leukemia and Lymphoma</i> , 2013, 54, 1989-1995.	1.3	65
47	The Natural History Of Polycythemia Vera In Two Diagnostic Eras. <i>Blood</i> , 2013, 122, 4078-4078.	1.4	1
48	Complex hypereosinophilia arising from post-polycythemia vera myelofibrosis: A case of imatinib-responsiveness. <i>Leukemia Research Reports</i> , 2012, 1, 9-12.	0.4	0
49	Janus kinase inhibitors. <i>Current Opinion in Oncology</i> , 2011, 23, 609-616.	2.4	31
50	Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms. <i>Thrombosis</i> , 2011, 2011, 1-8.	1.4	42
51	Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , 2011, 39, 95-101.	0.4	34
52	Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. <i>Haematologica</i> , 2011, 96, 1462-1469.	3.5	83
53	Tissue Factor Bearing Microparticles in the Myeloproliferative Neoplasms. <i>Blood</i> , 2011, 118, 5174-5174.	1.4	2
54	Age-Related Differences in Disease Characteristics and Clinical Outcomes in Polycythemia Vera. <i>Blood</i> , 2011, 118, 1758-1758.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Prognosis Is Genetically Fixed In Polycythemia Vera and Definable by Gene Expression Profiling. Blood, 2010, 116, 1987-1987.	1.4	0
56	Could the Increased Prevalence of Thrombotic Complications at High Altitude In Polycythemia Vera (PV) Be Contributed by Hypoxia?. Blood, 2010, 116, 1988-1988.	1.4	0
57	Disruption of the ASXL1 Gene Is Prevalent In PMF: Analysis of Molecular Genetics and Clinical Phenotypes. Blood, 2010, 116, 3074-3074.	1.4	0
58	Gender Differences In the Prevalence of Thrombosis In the JAK2 V617F-Positive Myeloproliferative Disorders. Blood, 2010, 116, 3080-3080.	1.4	1